Åslaug Helland

12.0k total citations · 1 hit paper
190 papers, 6.0k citations indexed

About

Åslaug Helland is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Åslaug Helland has authored 190 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Oncology, 82 papers in Pulmonary and Respiratory Medicine and 61 papers in Molecular Biology. Recurrent topics in Åslaug Helland's work include Lung Cancer Treatments and Mutations (57 papers), Cancer Genomics and Diagnostics (33 papers) and Lung Cancer Diagnosis and Treatment (27 papers). Åslaug Helland is often cited by papers focused on Lung Cancer Treatments and Mutations (57 papers), Cancer Genomics and Diagnostics (33 papers) and Lung Cancer Diagnosis and Treatment (27 papers). Åslaug Helland collaborates with scholars based in Norway, United States and Sweden. Åslaug Helland's co-authors include Odd Terje Brustugun, Anne‐Lise Børresen‐Dale, Gunnar B. Kristensen, Julien Mazières, Benjamin Besse, David Planchard, Egbert F. Smit, Vanessa Giannone, Anthony M. D’Amelio and Harry J.M. Groen and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Åslaug Helland

183 papers receiving 5.9k citations

Hit Papers

Dabrafenib plus trametini... 2017 2026 2020 2023 2017 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
    2017 948 citations Julien Mazières, Åslaug Helland et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Åslaug Helland 2.7k 2.7k 2.3k 1.8k 784 190 6.0k
Daniele Generali 2.5k 0.9× 3.1k 1.1× 1.7k 0.7× 2.1k 1.2× 475 0.6× 232 6.2k
Young Kwang Chae 2.6k 0.9× 3.1k 1.1× 1.9k 0.8× 1.7k 0.9× 820 1.0× 274 6.4k
Michael Millward 3.2k 1.2× 4.4k 1.6× 1.9k 0.9× 1.3k 0.7× 1.2k 1.5× 277 7.7k
Joel W. Neal 2.6k 0.9× 4.0k 1.5× 3.7k 1.6× 2.8k 1.5× 783 1.0× 259 7.8k
Christine M. Lovly 3.3k 1.2× 3.7k 1.4× 3.1k 1.4× 1.4k 0.8× 456 0.6× 143 6.8k
Sophie Postel‐Vinay 2.2k 0.8× 3.2k 1.2× 1.7k 0.7× 936 0.5× 951 1.2× 117 5.7k
Phuoc T. Tran 2.5k 0.9× 2.3k 0.8× 2.2k 1.0× 1.2k 0.7× 785 1.0× 254 6.4k
Wendy A. Cooper 2.0k 0.7× 2.5k 0.9× 2.9k 1.3× 1.4k 0.7× 561 0.7× 131 5.7k
Edwin M. Posadas 2.7k 1.0× 1.9k 0.7× 1.9k 0.8× 1.9k 1.0× 442 0.6× 173 5.6k
Mark N. Stein 2.3k 0.8× 2.5k 0.9× 2.1k 0.9× 1.3k 0.7× 880 1.1× 243 5.8k

Countries citing papers authored by Åslaug Helland

Since Specialization
Citations

This map shows the geographic impact of Åslaug Helland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Åslaug Helland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Åslaug Helland more than expected).

Fields of papers citing papers by Åslaug Helland

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Åslaug Helland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Åslaug Helland. The network helps show where Åslaug Helland may publish in the future.

Co-authorship network of co-authors of Åslaug Helland

This figure shows the co-authorship network connecting the top 25 collaborators of Åslaug Helland. A scholar is included among the top collaborators of Åslaug Helland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Åslaug Helland. Åslaug Helland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Helland, Åslaug, et al.. (2025). Effect of active external rewarming on esophageal temperature in simulated prehospital accidental hypothermia: a randomized crossover trial. Scandinavian Journal of Trauma Resuscitation and Emergency Medicine. 34(1). 8–8.
2.
Arribas, Alberto J., Luciano Cascione, Hege G. Russnes, et al.. (2025). Proteasome inhibition overcomes resistance to targeted therapies in B-cell malignancy models and in an index patient. Cell Death and Disease. 16(1). 555–555. 1 indexed citations
3.
Helland, Åslaug, et al.. (2025). Experimental hypothermia by cold air: a randomized, double-blind, placebo-controlled crossover trial. Scandinavian Journal of Trauma Resuscitation and Emergency Medicine. 33(1). 16–16. 2 indexed citations
4.
Miceli, Rosalba, Hanna Eriksson, Giuseppe Lo Russo, et al.. (2024). Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study. Acta Oncologica. 63. 213–219. 3 indexed citations
5.
Zhao, Zhi, et al.. (2024). Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma. Frontiers in Immunology. 15. 1480183–1480183.
6.
Helland, Åslaug, et al.. (2023). Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC. Frontiers in Oncology. 13. 1217424–1217424. 2 indexed citations
7.
Gelderblom, Hans, Anders Edsjö, Ulrik Lassen, et al.. (2023). 1711P The DRUP-like clinical trials family: A distributed European trial network for equitable access to precision medicine. Annals of Oncology. 34. S933–S934. 1 indexed citations
8.
Tourneau, Christophe Le, Fabrice André, Åslaug Helland, et al.. (2023). Modified study designs to expand treatment options in personalised oncology: a multistakeholder view. European Journal of Cancer. 194. 113278–113278. 3 indexed citations
9.
Helland, Åslaug, Sigbjørn Smeland, Hege G. Russnes, et al.. (2023). IMPRESS-Norway: Improving public cancer care by implementing precision cancer medicine in Norway.. Journal of Clinical Oncology. 41(16_suppl). e15188–e15188.
10.
Silwal‐Pandit, Laxmi, Henrik J. Johansson, Georgios Mermelekas, et al.. (2022). Proteome Analysis of Pancreatic Tumors Implicates Extracellular Matrix in Patient Outcome. Cancer Research Communications. 2(6). 434–446. 5 indexed citations
11.
12.
13.
Popat, Sanjay, Odd Terje Brustugun, J. Cadranel, et al.. (2021). Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. Lung Cancer. 157. 9–16. 13 indexed citations
14.
Helland, Åslaug, Simon Ekman, Anders Mellemgaard, et al.. (2020). Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study). Lung Cancer. 143. 27–35. 43 indexed citations
15.
Rye, Inga Hansine, Anne Trinh, Anna Barbro Sætersdal, et al.. (2018). Intratumor heterogeneity defines treatment‐resistant HER 2+ breast tumors. Molecular Oncology. 12(11). 1838–1855. 75 indexed citations
16.
Wei, Yongyue, Ruyang Zhang, Yichen Guo, et al.. (2018). Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC. Clinical Epigenetics. 10(1). 41–41. 5 indexed citations
17.
Dønnem, Tom, Sigurd M. Hald, Erna‐Elise Paulsen, et al.. (2015). Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer. Clinical Cancer Research. 21(11). 2635–2643. 252 indexed citations
18.
Fleischer, Thomas, Arnoldo Frigessi, Kevin C. Johnson, et al.. (2014). Genome-wide DNA methylation profiles in progression to in situand invasive carcinoma of the breast with impact on gene transcription and prognosis. Genome biology. 15(8). 435–435. 139 indexed citations
19.
Helland, Åslaug, et al.. (2008). Medikamentell behandling av alkoholabstinens. Tidsskrift for Den Norske Laegeforening. 3 indexed citations
20.
Wang, Yun, Gunnar B. Kristensen, Åslaug Helland, et al.. (2005). Protein Expression and Prognostic Value of Genes in the erb-b Signaling Pathway in Advanced Ovarian Carcinomas. American Journal of Clinical Pathology. 124(3). 392–401. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniele Generali Breakdown of academic impact, for papers by Young Kwang Chae Breakdown of academic impact, for papers by Michael Millward Breakdown of academic impact, for papers by Joel W. Neal Breakdown of academic impact, for papers by Christine M. Lovly Breakdown of academic impact, for papers by Sophie Postel‐Vinay Breakdown of academic impact, for papers by Phuoc T. Tran Breakdown of academic impact, for papers by Wendy A. Cooper Breakdown of academic impact, for papers by Edwin M. Posadas Breakdown of academic impact, for papers by Mark N. Stein
Rankless by CCL
2026